Commitment COM-301
Post-approval commitment for FDA-2024-0001. Category: Registry Study. Priority: medium.
Commitment ID
COM-301
Application
Authority
Food and Drug Administration
Category
Registry Study
Priority
medium
Status
Overdue
Due Date
2025-08-23
Completed At
—
Owner
Tomoko Ikeda
Created
2022-09-30
Description
Complete Phase IV post-marketing observational study (n=500)
Evidence (0)
No evidence documents attached. Upload evidence to mark this commitment as complete.